Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
EHA 2024 – In8bio bets on a registrational plan
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
Astra scoops JP Morgan
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Off-the-shelf Car-T from Caribou does enough at six months
Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.
